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ABSTRACT
Ovarian cancer (OC) has the highest rate of mortality among gynecological 
malignancy. Chemokine receptor CXCR2 in OC is associated with poor outcomes. 
However, the mechanisms by which CXCR2 regulates OC proliferation remain poorly 
understood. We generated CXCR2-positive cells from parental p53 wild-type (WT), 
mutant and null OC cells, and assessed the roles of CXCR2 on proliferation of OC cells 
in p53-dependent and independent manner. CXCR2 promoted cell growth rate: p53WT 
> mutant = null cells. Nutlin-3, a p53 stabilizer, inhibited cell proliferation in p53WT 
cells, but had little effect in p53-mutant or null cells, indicating p53-dependence of 
CXCR2-mediated proliferation. CXCR2 decreased p53 protein, a regulator of p21, and 
downregulated p21 promoter activity only in p53WT cells. The p53 responsive element 
(RE) of p21 promoter played a critical role in this CXCR2-mediated p21 downregulation. 
Moreover, CXCR2-positive cells activated more Akt than CXCR2-negative cells followed 
by enhanced murine double minute (Mdm2). Silencing Mdm2 or Akt1 upregulated p21 
expression, whereas Akt1 overexpression downregulated p21 at the promoter and 
protein levels in p53WT cells. Cell cycle analysis revealed that CXCR2 decreased p21 
gene in p53-null cells. Interestingly, romidepsin (histone deacetylase inhibitor)-induced 
p21 upregulation did not involve the p53 RE in the p21 promoter in p53-null cells. 
Romidepsin decreased the protein levels of Akt1 and Mdm2, leading to induction of p21 
in p53-null cells. CXCR2 reduced romidepsin-induced p21 upregulation by activating 
Akt-induced Mdm2. Taken together, CXCR2 enhances cell proliferation by suppressing 
p21 through Akt-Mdm2 signaling in p53-dependent and independent manner.
www.impactjournals.com/oncotarget/                   Oncotarget, 2018, Vol. 9, (No. 11), pp: 9751-9765
INTRODUCTION
Ovarian cancer is the deadliest gynecological 
cancer and the fifth leading cause of cancer-related deaths 
in women in the U.S [1]. Despite the heterogeneity 
on malignancies, ovarian cancer is simplified into two 
subtypes, type I and II tumors [2, 3]. Type I tumors include 
low-grade, mucinous, endometrioid and clear cells, in 
which the lesion is fully characterized, leading to a better 
prognosis. On the other hand, type II tumors consist of 
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high-grade serous and undifferentiated cells, wherein 
the lesion is not fully identified and is quite widespread, 
resulting in aggressiveness with a poor prognosis [2, 4, 
5]. In addition, type I tumors have genetic feature such as 
lack of mutation of p53, while type II tumors have high 
frequency of p53 mutation [2, 6]. 
Cumulative studies indicate that ovarian cancer 
is associated with chronic inflammation [7, 8]. 
Proinflammatory chemokines are now recognized as 
critical mediators in the tumor microenvironment and 
their amplified expression parallels to tumor growth, 
angiogenesis, and metastasis in many human cancers [9-
13]. CXC chemokines such as CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6 and CXCL8 induce potent angiogenesis 
mediated by the G-protein-coupled receptor CXCR2 [14, 
15]. Increasing evidence has implicated a high expression 
of CXCR2 in advanced stage of ovarian carcinomas 
leading to increased cancer progression and enhanced 
angiogenesis [16]. High expression of CXCR2 or its ligand 
CXCL1 leads to increased ovarian cancer proliferation, 
which is believed to be partly mediated by transactivation 
of EGFR signaling, and the suppression of CXCR2 leads 
to apoptosis [16, 17]. In addition to clear evidence of a 
role for CXCR2 in cancer progression, CXCR2 is known 
to influence oncogene-induced and replicative senescence 
through a DNA-damage [18]. The molecular mechanism 
of CXCR2 in cancer progression may include various 
signaling pathways such as mitogen-activated protein 
kinase (MAPK), phosphoinositide 3-kinase (PI3K), signal 
transducer and activator of transcription 3 (STAT3) and 
NF-κB pathways [16]. Our previous study confirmed the 
role of NF-κB signaling through EGFR-transactivated Akt 
on the CXCR2-driven ovarian cancer progression [19, 20]. 
Although CXCR2 regulates cell cycle through multiple 
signaling pathways, the mechanistic effects of CXCR2 on 
ovarian cancer cell proliferation is poorly understood. 
Despite advanced progress on the roles of the p53 
in regulating cell cycle and proliferation, little is known 
about how CXCR2 contributes to the proliferation of 
ovarian cancer in p53-dependent and independent 
manner. This study was designed to investigate 
the molecular mechanisms of CXCR2-mediated 
proliferation in p53 wild-type (WT), mutant and null 
ovarian cancer cells.
RESULTS
CXCR2 promotes cell proliferation in ovarian 
cancer cells
Based on representative human ovarian cancer cell 
lines, A2780 (p53WT, [21]), OVCAR-3 (p53-mutant 
R248Q, [22, 23]) and SKOV-3 (p53-null, [22, 24]), 
we generated CXCR2-negative (AA, OVA, SKA) and 
positive (ACXCR2, OVCXCR2, SKCXCR2) cells via 
stable transfection with empty vector and CXCR2 vector, 
respectively. Western blotting and confocal imaging 
analysis confirmed the relative expression levels of 
CXCR2 in the generated cell lines (Figures 1A and 1B). 
Thereafter, we compared cellular proliferation in CXCR2-
positive vs. negative cells. The proliferation was assessed 
at 24, 48 and 72 h. CXCR2-positive ovarian cancer 
cells significantly increased in proliferation compared to 
negative cells (Figure 1C). ACXCR2 cells had a higher 
proliferative rate than OVCXCR2 and SKCXCR2 cells 
(Figure 1C), indicating negative effects of CXCR2 on p53-
suppressed cell proliferation.
Nutlin-3 dramatically reduces proliferation 
of p53WT cells in which CXCR2 inhibits p21 
expression
We employed nutlin-3, a known inhibitor of p53-
Mdm2 (murine double minute) complex, to define 
inhibitory effects of CXCR2 on p53-dependent signaling. 
Nutlin-3 significantly inhibited cellular proliferation 
in p53WT AA and ACXCR2 cells in a dose-dependent 
manner (Figure 2A). At 10 µM of nutlin-3, ACXCR2 cells 
were more inhibited than AA cells, indicating sensitive 
response of CXCR2 on p53-dependent proliferation in 
p53WT cells. However, p53-mutant OVA/OVCXCR2 
and p53-null SKA/SKCXCR2 cells had a decreased trend 
on proliferation, but no significant change with nutlin-3 
treatment (Figure 2A). Moreover, SKA cells were more 
inhibited after treatment with nutlin-3 at high dosage 
(10 µM) compared to SKCXCR2 cells (Figure 2A), 
indicating the resistant response of CXCR2 on nutlin-
3-mediated inhibition of cell proliferation in p53-null 
cells. We then assessed if nutlin-3 could affect the protein 
levels of p53 and its transcriptional target p21. Nutlin-3 
upregulated p53 and p21 levels in a time-dependent 
manner in p53WT A2780 cells (Figure 2B). Nutlin-3 
blocked p53 degradation followed by increased p21 levels 
in p53WT (AA/ACXCR2) cells, but not in p53-mutant 
(OVA/OVCXCR2) or p53-null (SKA/SKCXCR2) cells 
(Figure 2C). CXCR2 reduced nutlin-3-mediated increase 
of p21 protein levels (Figure 2C). These results suggest 
negative effects of CXCR2 on the p53-dependent p21 
regulation of nutlin-3 only in p53WT cells. 
CXCR2 reduces p21 promoter activity in p53WT 
cells
We then checked if CXCR2 could affect the p21 
promoter activity in ovarian cancer cells with different 
p53 status. Transient transfection of CXCR2 reduced 
p21 promoter activity in p53WT A2780 cells, but had no 
effects in p53-mutant OVCAR-3 or p53-null SKOV-3 
cells (Figure 3A). To identify critical promoter regions to 
regulate p21, we determined the effect of CXCR2 on p21 
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luciferase activity in deleted constructs of p21 promoter 
[25]. The p53 responsive element (RE) (-1395/-1376) 
between p21P Δ800 and p21P Δ1.1k constructs played 
a critical role in CXCR2-mediated p21 downregulation 
in a p53-dependent manner (Figure 3B). Additionally, 
we checked the expression level of Mdm2, a negative 
regulator of p53 and an E3 ubiquitin ligase, in CXCR2-
negative and positive cells. CXCR2 upregulated Mdm2 
protein levels followed by decreased p53 and p21 protein 
levels in p53WT cells (Figure 3C). The p53-mutant and 
null cells also showed induced Mdm2 protein levels in 
response to CXCR2 (Figure 3C). Interestingly, CXCR2-
mediated Mdm2 induction downregulated p53 protein 
levels in p53-mutant cells (Figure 3C), despite the 
nonfunctional role of p53 mutant protein compared to 
p53WT protein.
CXCR2 activates Akt followed by induced 
Mdm2 protein to downregulate p53-dependent 
p21 expression in p53WT cells
To further assess the involvement of Mdm2 in 
CXCR2-mediated p21 downregulation, we utilized short 
interfering RNA (siRNA) to knockdown Mdm2 protein. 
Knockdown of Mdm2 induced p21 promoter activity 
and partially restored CXCR2-mediated inhibition of 
p21 promoter activity in p53WT A2780 cells (Figure 
4A). We verified that knockdown of Mdm2 upregulated 
the p53 and p21 protein levels (Figure 4B). It is well 
established that Akt induces Mdm2 [26]. Thus, we 
checked the expression level of Akt in CXCR2-negative 
or positive cells using confocal imaging. ACXCR2 cells 
expressed more activated Akt than AA cells (Figure 4C). 
Among the Akt isoforms, Akt1 was frequently elevated 
in ovarian cancer [27], and our representative ovarian 
cancer cell lines showed higher protein expression of Akt1 
[28]. Further, we made knockdown of Akt1 using siRNA 
to check the effects of Akt on p21 promoter luciferase 
activity. Knockdown of Akt1 significantly upregulated 
p21 promoter activity, and partially restored the CXCR2-
mediated downregulation of p21 promoter activity (Figure 
4D). Protein expression data validated this result that 
knockdown of Akt1 downregulated Mdm2 protein levels 
followed by the p53-dependent p21 upregulation (Figure 
4E). The transient transfection of Akt1 expression vector 
in A2780 cells led to the reduced p21 promoter activity and 
further caused the CXCR2-mediated p21 downregulation 
(Figure 4F). We validated that Akt1 overexpression 
upregulated Mdm2 protein followed by downregulation 
of the p53-dependent p21 protein expression (Figure 4G). 
Figure 1: Enhanced effects of CXCR2 on cell proliferation in ovarian cancer cells. (A–B) Confirmation of CXCR2 protein 
expression in CXCR2 stably transfected ovarian cancer cells A2780 (ACXCR2), OVCAR-3 (OVCXCR2) and SKOV-3 (SKCXCR2) 
versus their negative CXCR2 counterparts (AA, OVA, SKA), respectively, by western blot and confocal imaging analysis. β-actin was 
detected as an internal loading control of cell lysates. A representative result is shown from duplicated experiments. (C) CXCR2 promotes 
increase cellular proliferation in CXCR2-positive cells compared to its negative cells. All data are shown as mean ± SE from triplicated 
experiments. * indicates a significant increase (p ≤ 0.05) by Student’s t-test at appointed time points.
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Figure 2: The p53-dependent effects of nutlin-3 on cell proliferation and p21 levels in p53WT, mutant and null cells. (A) The 
p53-dependent effect of nutlin-3 on cell proliferation in CXCR2-negative vs. positive cells with different p53 status. All data are shown as mean 
± SE from triplicated experiments. # and * indicate a significant decrease and increase (p ≤ 0.05) by ANOVA and Student’s t-test, respectively. 
(B) Time-dependent effect of nutlin-3 on p53 and its downstream p21 expression in p53WT A2780 cells. (C) Comparative induction of nutlin-3 
on p53 and p21 protein levels in p53WT cells (AA/ACXCR2), p53-mutant (OVA/OVCXCR2) and p53-null (SKA/SKCXCR2) cells. β-actin 
was detected as an internal loading control of cell lysates. A representative result is shown from duplicated experiments. 
Figure 3: Negative effects of CXCR2 on p21 promoter activity in a p53-dependent manner. (A) Differential effects of 
CXCR2 on p21 promoter activity in p53WT A2780 cells, p53-mutant OVCAR-3 and p53-null SKOV-3 cells. (B) The p53-dependent 
inhibition of CXCR2 on p21 promoter activity in deleted constructs of p21 promoter in p53WT A2780 cells. All data are shown as mean ± 
SE from triplicated experiments. (C) Induced effects of CXCR2 on Mdm2 protein in p53-dependent p21 regulation. β-actin was detected 
as an internal loading control of cell lysates. A representative result is shown from duplicated experiments. # indicates a significant increase 
(p ≤ 0.05) in each pair by Student’s t-test.
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These results indicate that CXCR2 suppresses cell cycle 
inhibitor p21 protein, probably by downregulating p53 via 
Akt-Mdm2 axis. 
CXCR2 negatively regulates cell cycle inhibitor 
p21 in p53-null ovarian cancer cells
We demonstrated that CXCR2 suppressed p53-
dependent p21 upregulation in p53WT cells. However, 
we wondered if CXCR2 could negatively regulate p21 in 
p53-independent manner in p53-null ovarian cancer cells. 
CXCR2 has been implicated in cell cycle and apoptosis 
via several molecular pathways in ovarian cancer [16]. 
Because CXCR2 accelerated cell proliferation in p53-
null SKCXCR2 cells (Figure 1C), we assessed if there 
could be any changes in cell cycle between SKA and 
SKCXCR2 cells. First, we determined the differential 
effects of CXCR2 on cell cycle in SKA and SKCXCR2 
cells based on parental p53-null SKOV-3 cells. Flow 
cytometry analysis revealed that SKCXCR2 cells had a 
significant decrease in G0-G1 phase and increase in S 
and G2-M phases compared to SKA cells (Figure 5A). In 
addition, we compared PCR array for cell cycle-related 
regulatory genes between SKA and SKCXCR2 cells. 
Cyclin-dependent kinase inhibitor 1 (CDKN1A, p21) 
mRNA was maximally down-regulated in SKCXCR2 
cells compared to SKA cells (Figure 5B), despite no 
expression of p21 protein in p53-null cells (Figure 2C). 
Since Akt signaling was involved in CXCR2-mediated 
p21 downregulation in p53WT cells, we investigated 
whether CXCR2 could regulate p21 in p53-null cells in 
a similar way. Akt signaling is well known to regulate 
cell proliferation and survival [29–31]. Thus, we assessed 
Akt status between p53-null SKA and SKCXCR2 cells. 
Figure 4: Inhibitory effects of CXCR2-derived Akt-Mdm2 axis on p53-dependent p21 protein expression in p53WT 
cells. (A) Knockdown of Mdm2 increased p21 promoter activity and recovered the CXCR2-mediated downregulation of p21. (B) 
Confirmation of the knockdown of Mdm2 protein through western blot and the effect of knockdown of Mdm2 protein on p53-dependent 
p21 protein expression. (C) Comparison of Akt activation in AA and ACXCR2 cells by confocal imaging analysis. (D) Knockdown of 
Akt1 increased p21 luciferase activity and recovered the CXCR2-mediated downregulation of p21. (E) Confirmation of the knockdown 
of Akt1 through western blot and the effect of knockdown of Akt1 on Mdm2, p53 and p21 protein expression levels. (F) Overexpression 
of Akt1 decreased the p21 luciferase activity and further abated the CXCR2-mediated downregulation of p21. (G) Confirmation of the 
overexpression of Akt1 through western blotting and the effect of silencing Akt1 on Mdm2, p53 and p21 protein expression. β-actin 
was detected as an internal loading control of cell lysates. All data are shown as mean ± SE from triplicated experiments (A, D, F) and 
a representative result is shown from duplicated experiments (B, C, E, G). * and # indicate a significant increase and decrease (p ≤ 0.05), 
respectively, by Student’s t-test.
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Confocal imaging analysis showed more activated Akt 
in SKCXCR2 compared to SKA cells (Figure 5C). The 
CXCR2-mediated downregulation of p21 might be related 
to uncontrolled proliferation of p53-null cells, plausibly 
involving constitutively activated Akt.
Romidepsin does not involve specific p53 RE of 
p21 promoter to regulate p21 in p53-null cells
CXCR2 had no effects on p21 promoter activity 
in p53-null SKOV-3 cells (Figure 3A). Furthermore, 
p53-null SKA and SKCXCR2 cells did not express p21 
protein at basal levels (Figure 3C) despite CXCR2-
mediated downregulation of p21 mRNA in p53-null 
cells (Figure 5B). Romidepsin (FK228), a histone 
deacetylase inhibitor (HDACi), is known to induce 
p21 protein specifically even in p53-null SKOV-3 
cells [32, 33]. We employed romidepsin to induce p21 
protein and determined if CXCR2 affected romidepsin-
induced p21 protein expression levels in p53-null cells. 
Although CXCR2 decreased p21 promoter activity in 
p53WT cells (Figure 3a), p53-null cells had no effects 
on p21 promoter activity in response to CXCR2 (Figure 
6A). Romidepsin increased the p21 promoter activity 
and CXCR2 further potentiated romidepsin-induced 
p21 upregulation (Figure 6A). In addition, romidepsin 
increased p21 promoter activity in a dose-dependent 
manner (Figure 6B). Moreover, we assessed the effect 
of romidepsin on p21 promoter activity in deleted 
constructs of p21 promoter. Romidepsin had a similar 
response to all deleted constructs, including p53 RE 
deletion (Figure 6C), indicating no specific binding site 
for p53 RE to regulate p21 in p53-null cells. 
CXCR2-expressing cells are more resistant to 
the anti-tumor effect of romidepsin through p21 
downregulation 
We assessed differential effects of CXCR2 on 
romidepsin-induced p21 protein in SKA and SKCXCR2 
cells. SKA cells increased p21 protein expression 
levels in response to romidepsin in a dose-dependent 
manner (Figure 7A). On the other hand, SKCXCR2 
showed reduced romidepsin-induced p21 protein levels 
compared to SKA cells (Figure 7A). We compared 
IC50 of romidepsin in SKA and SKCXCR2 cells. 
SKCXCR2 cells had a higher IC50 of romidepsin (46.2 
nM) compared to SKA cells (35.6 nM) (Figure 7B). 
Finally, we checked clonogenic survival assay after 
treatment with romidepsin in SKA and SKCXCR2 cells. 
SKCXCR2 cells had increased colony number compared 
to SKA cells at 32 nM of romidepsin below IC50 (Figure 
7C). At 64 nM of romidepsin above IC50, both SKA 
and SKCXCR2 cells had similarly few colony numbers 
(Figure 7C). 
CXCR2 downregulates romidepsin-induced p21 
protein expression through the Akt-Mdm2 axis 
in p53-independent manner in p53-null cells
Since CXCR2 negatively regulated p21 through the 
Akt-Mdm2 axis in p53-dependent manner, we assessed if 
romidepsin utilized the Akt-Mdm2 axis to regulate p21 
in p53-independent manner and if the CXCR2-activated 
Akt-Mdm2 axis could reduce romidepsin-induced 
p21 protein expression in p53-null cells. Romidepsin 
decreased Akt1 and Mdm2 protein levels followed by 
induced p21 protein expression levels in SKOV-3 cells in 
a dose-dependent manner (Figure 8A). Since SKCXCR2 
cells expressed higher Akt and Mdm2 protein levels 
compared to SKA cells (Figures 3C and 5C), we then 
used SKCXCR2 cells to check if silencing Akt1 and 
Mdm2 could regulate romidepsin-induced p21 protein 
expression in a p53-independent manner. Knockdown 
of Akt1 decreased Mdm2 protein levels followed by 
enhanced romidepsin-induced p21 protein levels (Figure 
8B). Although knockdown of Mdm2 had no effects on 
Akt protein levels, it increased romidepsin-induced p21 
protein levels compared to control siRNA (Figure 8B). 
In addition, we overexpressed Akt1 into SKOV-3 cells to 
check if Akt-Mdm2 axis could reduce romidepsin-induced 
p21 protein expression in a p53-independent manner. 
Akt1 overexpression increased Mdm2 protein levels 
followed by reduction of romidepsin-induced p21 protein 
expression in p53-null SKOV-3 cells (Figure 8C). 
DISCUSSION 
Our main finding is that CXCR2 negatively 
regulates p21 via Akt-mediated Mdm2 in p53-dependent 
and independent manner in ovarian cancer cell 
proliferation. Our previous study showed that CXCR2 
transactivated EGFR, leading to Akt activation [19]. The 
Akt activation induces Mdm2, a key negative regulator 
of p53 [34]. Akt-mediated Mdm2 induction can increase 
p53 degradation which further inhibits cell cycle arrest 
protein p21 in a p53-dependent manner. The reduced p21 
can enhance cell proliferation, reinforcing ovarian cancer 
progression followed by high mortality rate. Furthermore, 
CXCR2 inhibits HDACi-induced p21 in p53-null ovarian 
cancer cells via Akt-mediated Mdm2 in a p53-independent 
manner. 
CXCR2-positive cells proliferated faster than 
CXCR2-negative cells, indicating that CXCR2 is a 
proliferative factor in ovarian cancer. Patients with highly 
CXCR2 expressed ovarian cancer had short survival 
compared to patients with low CXCR2 levels [16]. The 
p53WT cells are more responsive to CXCR2-mediated 
proliferation than p53-mutant and null cells, although all 
are somewhat responsive to CXCR2. Based on this fact, 
CXCR2 is likely inducing cell proliferation in both p53-
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dependent and independent manner in p53WT cells. On 
the other hand, p53-mutant and null cells are likely to only 
involve p53-independent CXCR2-induced proliferation. It 
is well established that Mdm2 interacts directly with p53, 
leading to loss of functional p53 roles [35]. Nutlin-3, a 
specific inhibitor of Mdm2 and stabilizing agent of p53WT 
[36], has anti-proliferative effects in p53WT cells, but not 
in p53-mutant and null cells, implying that nutlin-3 is p53-
dependent. Furthermore, nutlin-3-stabilized p53 increased 
the expression levels of p21, a well-known direct p53 
response gene. Despite similarity of nutilin-3 stabilized 
p53 levels between AA and ACXCR2 cells, CXCR2 
reduced nutlin-3-induced p21, probably involving p53-
independent mechanisms of CXCR2 in p21 regulation. 
In addition, CXCR2-mediated decrease of p21 promoter 
activity in p53WT cells, but not in p53-mutant and null 
cells, involves critical p53 RE in p21 promoter which 
indicates p53-dependent effects of CXCR2. 
Many human cancers showed overexpressed 
Mdm2 [37, 38]. CXCR2 induced Mdm2 protein levels 
irrespective of p53 status in ovarian cancer cells. Some 
studies have shown that Akt stimulates the phosphorylation 
and translocation of Mdm2 into the nucleus, where it binds 
to p53 followed by loss of functional p53 roles [39–41]. 
Promoter, knockdown and overexpression studies have 
revealed that Akt-induced Mdm2 plays a critical role 
in CXCR2-mediated proliferation of ovarian cancer by 
inhibiting p53 function to induce p21. Therefore, CXCR2 
could mediate Akt-induced Mdm2, resulting in inhibition 
of p53-dependent p21 upregulation in p53WT ovarian 
cancer, followed by increased cell proliferation and finally 
high mortality rate. 
Almost all ovarian cancers (above 96%) are p53 
mutant or null resulting in non-functional p53 activity, 
and p53WT ovarian cancers are rare [21]. In addition, 
p53-null status might be more metastatic than p53-mutant 
in ovarian cancer [42]. We selected p53-null SKOV-
3 cells to clarify p53-independent effects of CXCR2 in 
cell proliferation. Because p53-null SKOV-3 cells did 
not express p21 protein at basal levels, romidepsin, a 
FDA approved HDAC class I inhibitor, was used as a 
p21 inducer in p53-independent manner as described 
previously [32, 33]. HDACs are important players in 
cancer development and progression [43]. HDACs 
Figure 5: Differential effects of CXCR2 on cell cycle between p53-null SKA and SKCXCR2 ovarian cancer cells. 
(A) Comparison of cell cycle between SKA and SKCXCR2 cells by flow cytometry. All data are shown as mean ± SE from triplicated 
experiments. *indicates a statistical significance (p ≤ 0.05) by Student’s t-test. (B) Comparison of cell cycle related genes between SKA and 
SKCXCR2 cells by PCR array. The dotted line indicates a 0.5-fold increase; those with a <0.5-fold increase and average cycle threshold 
>30 are recognized as down-regulated genes. All data are shown as average from duplicated experiments. (C) Comparison of Akt status 
between SKA and SKCXCR2 cells by confocal imaging. A representative result is shown from duplicated experiments.
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were recruited to gene promoters to suppress the tumor 
suppressors and cell-cycle inhibitors [43, 44]. Treatment 
of cancer cells with HDACi results in apoptosis [45]. Cell 
cycle inhibitor p21 is one of the frequently induced gene 
by HDACi via releasing the repressor HDAC1 from its 
promoter [44–46]. Since romidepsin induces the activity 
of deleted p21 promoters even without p53 RE in p53-null 
cells, it is not likely to involve a specific region in p21 
promoter to regulate p21 in a p53-independent manner. 
Furthermore, CXCR2-mediated downregulation of p21 
promoter activity in p53WT cells could not be observed 
in p53-null cells. However, CXCR2 decreases romidepsin-
induced p21 protein expression levels in p53-null cells. 
Based on the negative effects of CXCR2 on romidepsin-
induced p21, IC50 of romidepsin and clonogenic colony 
formation, CXCR2 could be resistant to romidepsin 
treatment in ovarian cancer. The resistance to anti-tumor 
effect of romidepsin in CXCR2-positive cells might be 
due to the over-amplification of phosphorylated Akt. The 
Akt phosphorylation was implicated in deviating apoptotic 
signals in liver cancer [47], and the constitutive activation 
of Akt induced chemo- and radio-therapeutic resistance 
in small-cell lung cancers and gastric cancers [48, 49]. 
In human leukemia K562 cells, the HDAC6 inhibitor 
disrupts the antiapoptotic pathway of Akt [50]. We have 
confirmed that CXCR2 mediates Akt-induced Mdm2 in 
p53-null cells as observed in p53WT cells. Interestingly, 
romidepsin-induced p21 involves Akt-induced Mdm2 in 
a p53-independent manner by downregulating Akt and 
Mdm2 protein levels. CXCR2 is likely to activate Akt, 
leading to induction of Mdm2 which blocks p21. On the 
other hand, romidepsin is likely to downregulate Akt, 
leading to reduction of Mdm2 which potentiates p21.
In summary, CXCR2-driven ovarian cancer 
progression directly upregulates its own ligands such 
as CXCL1 and CXCL2 [19]. The released CXCL1 and 
CXCL2 binds to CXCR2, leading to activated EGFR 
[19]. The activated EGFR leads to phosphorylation of 
Akt, which directly upregulates Mdm2. The Akt-induced 
Mdm2 can suppress anti-tumor role of p53 followed by 
downregulation of cell cycle arrest protein p21, a p53 
transcriptional target gene, which in turn can prompt cell 
proliferation, faster cancer progression and finally higher 
mortality rate (Figure 8D). HDACi like romidepsin is well 
known to induce p21 in p53-null ovarian cancer cells [32, 
33], which can suppress the Akt-induced Mdm2 followed 
Figure 6: Effects of romidepsin on p21 promoter activity in p53-null SKOV-3 cells. (A) Effects of CXCR2 on romidepsin-induced 
p21 promoter activity in SKOV-3 cells. (B) Dose-dependent effects of romidepsin on p21 luciferase activity in SKOV-3 cells. Experiments 
were performed in triplicate and all data are shown as mean ± S.E. *(p ≤ 0.05) in each group by ANOVA and Tukey’s pairwise comparisons. 
(C) Effects of romidepsin on p21 promoter activity in deleted constructs of p21 promoter p53 response element in p53-null SKOV-3 cells. All 
data are shown as mean ± SE from triplicated experiments. *indicates a statistical significance (p ≤ 0.05) by Student’s t-test.
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by slower cell proliferation and lower mortality rate 
(Figure 8D). CXCR2 enhances the Akt-induced Mdm2 
which inhibits HDACi-induced p21 in a p53-independent 
manner, leading to faster cancer progression and higher 
mortality rate (Figure 8D). Conclusively, CXCR2 is a 
negative regulator of p21 via the Akt-induced Mdm2 in 
p53-dependent and independent manner in ovarian cancer.
MATERIALS AND METHODS
Reagents
Romidepsin (FK228) was obtained from Gloucester 
Pharmaceuticals (Cambridge, MA, USA). Pre-designed 
siRNAs for non-targeting Control, Akt1 and Mdm2 
were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Nutlin-3 was obtained from 
R&D Systems (Minneapolis, MN, USA). Antibodies 
were purchased as follows: Akt, p21 (waf1/cip1), Akt 
isoform and Akt phosphorylated form (pAkt, Ser473) 
from Cell Signaling Technology (Beverly, MA, USA) 
and p53, Mdm2, CXCR2, and β-actin from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Fluorescein 
isothiocyanate-conjugated anti-CXCR2 (FAB331F, 1:1) 
was from R&D Systems (Minneapolis, MN, USA) and 
propidium iodide was from Sigma-Aldrich (St. Louis, 
MO, USA). PCR array for the cell cycle, SYBR® Green 
Master Mix, RNeasy Mini Kit and RNase-free DNAse 
set came from SABiosciences in Qiagen (Frederick, 
MD, USA). Chemiluminescent detection kits were from 
GE Healthcare (Piscataway, NJ, USA). Penicillin G/
streptomycin, Lipofectamine 2000 and all liquid culture 
media were acquired from Invitrogen (Grand Island, NY, 
USA). Mycoalert mycoplasma detection kit was from 
Lonza (Allendale, NJ, USA). G418-sulfate was purchased 
from Cayman Chemical (Ann Arbor, MI, USA). Finally, 
the Luciferase Reporter Assay System was obtained from 
Promega (Madison, WI, USA).
Stable CXCR2 expressing cell lines and cell 
cultures
All cells were routinely tested for mycoplasma 
(Lonza, Allendale, NJ, USA) contamination according 
Figure 7: Resistant effects of CXCR2 on the anti-tumor potential of romidepsin in p53-null cells. (A) Inhibitory effects of 
CXCR2 on romidepsin-induced p21 protein in SKA and SKCXCR2cells. Cells were treated with romidepsin (0, 32 and 64 nM) for 24 h. 
β-actin was detected as an internal loading control of cell lysates. A representative result is shown from duplicated experiments. (B) IC50 
of romidepsin in SKA and SKCXCR2 cells. Cells were treated with 10–100 nM romidepsin for 48 h and then cell proliferation assay was 
performed. All data are shown as mean ± SE from triplicated experiments. *indicates a significant increase (p ≤ 0.05) by Student’s t-test. (C) 
Clonogenic survival assay in SKA and SKCXCR2 after treatment of romidepsin (0, 32 and 64 nM) for 48 h. * (p ≤ 0.05) in each group by 
ANOVA and Tukey’s pairwise comparisons. All data are shown as mean ± SE from triplicated experiments. Each SE is located within circles.
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to the manufacturer’s protocol. Human ovarian cancer 
cell lines OVCAR-3 (p53-mutant) and SKOV-3 (p53-
null) were purchased from the American Type Culture 
Collection (Manassas, VA, USA). A2780 (p53 wild-
type) was kindly provided by Dr. Andrew Godwin 
(University of Kansas Cancer Center, Kansas City, KS, 
USA). CXCR2 expression vector was kindly provided 
by Dr. Ann Richmond (Vanderbilt University, Nashville, 
TN, USA) [51, 52]. Stable CXCR2 expressing cell 
lines were generated by transfecting CXCR2 or empty 
vectors into parental A2780, OVCAR-3 and SKOV-3 
cells. Briefly, subconfluent cells were transfected with 
CXCR2 or empty vectors using lipofectamine 2000 and 
then treated with G418 to select drug-resistant clones. The 
cells were treated every 3 days with G418 until resistant-
clones appeared. The expression of CXCR2 protein in 
the selected clones was confirmed by western blot and 
confocal imaging analysis. The CXCR2-positive cell 
lines were termed ACXCR2, OVCXCR2 and SKCXCR2 
and the CXCR2-negative control cell lines, AA, OVA, 
and SKA, respectively. The cells were cultured in RPMI 
medium containing penicillin/streptomycin and 10% FBS 
at 37° C in a water-saturated atmosphere of 95% air and 
5% CO2. 
Cell proliferation assays
Cell proliferation assays were performed using 
the cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to a colored product. 
After incubation in a 24-well plate, each well was washed 
twice with phosphate-buffered saline (PBS) and then 
MTT solution (1 mg/ml of phenol red-free media: PBS 
= 4:1) was added. The plates were incubated for 3 h with 
protection from light. The MTT solution was removed and 
500 µl of isopropanol was added. The plates were placed 
Figure 8: Negative effects of CXCR2 on romidepsin-induced p21 protein expression via Akt-Mdm2 axis in a p53-
independent manner. (A) Dose-dependent effects of romidepsin on Akt, Mdm2 and p21 protein expression in p53 null SKOV-3 cells. 
Cells was treated with 0, 4, 8, 16, 32 and 64 nM romidepsin for 24 h. (B) Effects of silencing Akt1 and MDM2 on romidepsin-induced 
p21 protein expression in SKCXCR2 cells. (C) Effects of overexpressed Akt1 on romidepsin-induced p21 protein expression in SKOV-3 
cells. β-actin was detected as an internal loading control of cell lysates. Cells was treated with 64 nM romidepsin for 24 h. (D) Schematic 
representation of molecular mechanism of CXCR2-mediated Akt-Mdm2 axis on cell cycle inhibitor p21 regulation in p53-dependent and 
independent manner in ovarian cancer cells. A representative result is shown from duplicated experiments.
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on a shaker for 10 min at room temperature to thoroughly 
dissolve the MTT color product. Optical density was 
measured at 595 nm using a microplate reader (Bio-Rad, 
Hercules, CA, USA). Values were normalized to untreated 
controls.
Confocal imaging analysis
Cells (5000 cells/250 µl media) were seeded on 
8-chambered slides and cellular attachment was allowed 
overnight. The cells in the chamber slides were washed 
3 times in PBS and fixed with 4% paraformaldehyde for 
10 min at room temperature and blocked with 1% BSA in 
PBS for 30 min. The primary antibody was applied for 1 
h at room temperature, and then washed 3 times with PBS 
for 30 min. The slides were then incubated with the second 
antibody conjugated with Alexa Fluor 594 or Alexa Fluor 
488 (LI-COR Biotechnology, Lincoln, NE, USA) for 1 h at 
room temperature. Finally, the slides were washed 3 times 
with PBS, mounted with mounting medium containing 
DAPI (Vector laboratories, Burlingame CA, USA) and 
observed with a fluorescence microscope (Nikon A1R 
laser scanning confocal imaging).  
Flow cytometry
Cell cycle status were detected by flow cytometry 
using protocols described previously [53]. Cancer cells 
were seeded at equal densities and maintained in culture 
for 24 h. Briefly, 1 × 106 cells of SKA and SKCXCR2 cells 
were harvested and washed twice with PBS. The cells 
were fixed on ice-cold 75% ethanol at 4° C for a minimum 
of 4 h and then washed twice with PBS. The cells were 
then treated with RNAse (Sigma-Aldrich) in a 37° C water 
bath for 20 minutes, then finally stained with propidium 
iodide [50 mg/ml in 0.1% (w/v) sodium citrate, 0.1% (v/v) 
Triton X-100] overnight. The cells were then analyzed by 
flow cytometry (FACStation, BD Biosciences) and the 
percentage of cells in G0/G1, S and G2/M phases were 
quantified utilizing FlowJo software (Tree Star Inc., 
Ashland, OR, USA). The assay was repeated in triplicate. 
Western blotting
Total whole-cell lysates were prepared, fractionated 
on SDS-polyacrylamide gels, and transferred to 
polyvinylidene difluoride membrane as described 
previously [54]. The total protein extract for each cell line 
was obtained by using a lysis buffer and equal amounts 
(30 µg per load) were analyzed by immunoblotting. 
Blocking of nonspecific proteins was performed by 
incubation of the membranes with 5% nonfat dry milk 
in Tris buffered saline Tween-20 (TBST) for 2 h at room 
temperature. Blots were incubated with primary antibodies 
at 1:1,000 dilution in blocking solution overnight at 4° C. 
The membranes were washed 3 times with TBST for 10 min, 
followed by incubation for 1 h with horseradish peroxidase 
conjugated secondary antibody (1:2,500 dilution) in 
5% milk/TBST. The membranes were then rinsed 3 
times with TBST for 10 min and the bands visualized by 
enhanced chemiluminescence. β-actin (sc-1616, Santa Cruz, 
CA, USA) was detected as an internal loading control of 
cell lysates. 
Transient transfection
Ovarian cancer cells were seeded to approximately 
75% confluence in 6-well plates, were washed and 
transiently transfected with previously constructed 
HA epitope-tagged Akt1 [55], which was a kind gift 
from Dr. Joseph Testa (Fox Chase Cancer Center, 
Philadelphia, PA, USA). Briefly, cells were transfected 
with Akt1 or pcDNA3 expression vector (control) for 
16 h at 37° C using Lipofectamine™ 2000 (Invitrogen 
Life Technologies, Grand Island, NY, USA), following 
manufacturer’s instructions. Transfection efficiencies 
were determined by western blot, and treated as outlined 
in Results. 
Luciferase assay
Ovarian cancer cells were seeded to approximately 
75% confluence in 24-well plates, were washed and 
transiently transfected with p21 promoter subcloned 
into pGL2-basic luciferase reporter vector (a gift 
from Dr. Xiao-Fan Wang, Duke University Medical 
Center, Durham, NC, USA) for 16 h at 37° C using 
Lipofectamine™ 2000 (Invitrogen Life Technologies, 
Grand Island, NY, USA). Transfected cells were treated 
as outlined in Results and incubated for 16 h. Cells 
were then rinsed with ice-cold PBS and lysed with lysis 
buffer (Promega, Madison, WI), and finally cell lysates 
were used for determination of luciferase activity using a 
microplate luminometer. Luciferase activity, expressed as 
relative light units, was normalized to measured protein 
levels. 
Knockdown of Mdm2 and Akt1
Cells at approximately 75% confluency in 6-well 
plates were washed once with 1% FBS fresh media without 
additives and then transiently transfected with Control 
or Akt1 and Mdm2 specific siRNA (final concentration: 
100 nM) for 72 h at 37° C using Lipofectamine solution. 
Transfected cells were confirmed knockdown of Akt1 and 
Mdm2 protein using western blots, and treated as outlined 
in Results according to various experiments.
PCR array for cell cycle genes
Total RNAs were isolated from SKA and SKCXCR2 
cells using RNeasy Mini Kit (Qiagen). Genomic DNA 
contamination was eliminated using the RNase-free 
DNAse set (Qiagen). cDNA was synthesized by RT 
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reaction at 42° C for 15 min followed by 94° C for 5 
min. A real-time PCR reaction was performed using the 
Human Cell Cycle RT2 Profiler PCR array (Qiagen) on a 
Bio-Rad CFX96 (Hercules, CA, USA) and the following 
two-step cycling program: 1 cycle at 95° C for 10 min, 
and 40 cycles at 95° C for 15 sec and at 60° C for 1 min. 
Data analysis was performed based on a Web-Based PCR 
Array Data Analysis (http://pcrdataanalysis.sabiosciences.
com/pcr/arrayanalysis.php) provided by SABiosciences in 
Qiagen (Frederick, MD, USA).
Clonogenic survival assay
Cells were grown in 6-well plates to 75% 
confluence, and then treated with vehicle or romidepsin 
for 48 h. After collecting cells with trypsin, 1000 cells/ml 
were then reseeded into 6-well plates and incubated with 
fresh media for an additional 7 days. Cells were fixed in 
methanol and then stained with (0.25% methylene blue 
in 50% methanol) for 30 min at room temperature. After 
washing with PBS and air-drying the plates, colonies were 
counted. The data were expressed as percent survival 
relative to the control.
Statistical analysis
Data were analyzed by the paired Student’s t-test and 
one-way analysis of variance (ANOVA) as appropriate. 
If a statistical significance (p ≤ 0.05) was determined 
by ANOVA, the data were further analyzed by Tukey’s 
pairwise comparisons to detect specific differences 
between treatment groups.
Abbreviations
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